Literature DB >> 15559059

Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications.

Michael Y Chang1, David J Sugarbaker.   

Abstract

Innovative therapeutic agents and strategies are being investigated to improve survival with this lethal disease. New chemotherapy agents, including gemcitabine (Eli Lilly and Company; Indianapolis, Indiana) and pemtrexed (Eli Lilly and Company) show promise against mesothelioma. Kaiser has reported using novel therapies, such as cytokines and suicide gene therapy, to target mesothelioma. Pass et al , Moskal et al , Schouwink et al , and Friedberg et al have applied photodynamic therapy to the hemithorax after surgical resection. Because recurrence of mesothelioma after surgical resections tends be locoregional rather than distant , strategies to improve local control may be beneficial. Several groups, including our Brigham and Women's Hospital Thoracic Surgery Division and Dana Farber Thoracic Oncology Program, are investigating intraoperative intracavitary lavage of hyperthermic chemotherapy immediately after EP (discussed elsewhere in this issue). Although mesothelioma remains a difficult disease to treat, the techniques of surgical resection for mesothelioma have improved dramatically. Currently, EPP can be performed with acceptable morbidity and mortality at experienced centers.

Entities:  

Mesh:

Year:  2004        PMID: 15559059     DOI: 10.1016/j.thorsurg.2004.06.001

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  8 in total

1.  Use of postoperative creatinine to predict sustained kidney injury in patients undergoing mesothelioma surgery.

Authors:  K Annette Mizuguchi; Aya Mitani; Sushrut S Waikar; Peter Ireland; Christia Panizales; Gretchen Deluke; David J Sugarbaker; Joseph V Bonventre; Gyorgy Frendl
Journal:  Clin J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 8.237

2.  Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.

Authors:  Valerie W Rusch
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 4.  Local and systemic therapies for malignant pleural mesothelioma.

Authors:  Daniel Gomez; Anne S Tsao
Journal:  Curr Treat Options Oncol       Date:  2014-12

5.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

6.  The evolution of multimodality therapy for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Curr Treat Options Oncol       Date:  2011-06

7.  Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.

Authors:  Gavin J Gordon; Lingsheng Dong; Beow Y Yeap; William G Richards; Jonathan N Glickman; Heather Edenfield; Madhubalan Mani; Richard Colquitt; Gautam Maulik; Branden Van Oss; David J Sugarbaker; Raphael Bueno
Journal:  J Natl Cancer Inst       Date:  2009-04-28       Impact factor: 13.506

8.  Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles.

Authors:  Brock C Christensen; Carmen J Marsit; E Andres Houseman; John J Godleski; Jennifer L Longacker; Shichun Zheng; Ru-Fang Yeh; Margaret R Wrensch; Joseph L Wiemels; Margaret R Karagas; Raphael Bueno; David J Sugarbaker; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.